8 Best Hematology Startups to Watch in 2025

The Definitive Seedtable Ranking of Hematology Startups

We track 71,000+ companies and rank them dynamically using our Seedtable Score – a score that uses quantitative and qualitative data points to signal the momentum behind a company. We then monitor the list manually leveraging our expertise as founders and investors.

There are 8 start-ups with an aggregate funding of $2.6b. The average funding per company in this subset is $327.5m.

Last update to the database: Feb 18, 2025. See changelog.

See all results for this search

Track over 71,000 companies

Discover
Fast-growing Global startups

Seedtable uses technology and people to track over 71,000 companies to help you find the right ones to partner with.

Pricing + Sign up

8

Funding Rounds

$967.6m

Money raised

Freenome is a San Francisco-based company which uses genetic analysis for early cancer detection and risk assessment.

1

Funding Rounds

$1.0m

Money raised

Sanguine is a company that has the mission to accelerate medical research by eliminating the barriers to patient participation.

3

Funding Rounds

$1.4b

Money raised

Resilience Technology Corporation is an Hanover, Maryland-based cybersecurity company developing and manufacturing cyber security tools and founded in 1995.

Key people:

2

Funding Rounds

$18.5m

Money raised

AI-powered, FDA-cleared blood cell morphology platform replaces manual lab microscopy, helping hematologists and hematopathologists to detect cancers and blood-related diseases.

Location:

Key people:

10

Funding Rounds

$13.5m

Money raised

NuvOx Pharma is an oxygen therapeutics company founded in 2008 by David Wilson.

1

Funding Rounds

$30.0m

Money raised

A biotechnology company developing treatments for hematology and oncology diseases

2

Funding Rounds

$4.8m

Money raised

The Hemarina technological platform is based on the peculiarities of the purified hemoglobin of lugworms, Arenicola marina . Its structure is comparable to that of human hemoglobin, however it is distinguished by: its extracellular character (it is not contained in a red blood cell), and therefore universal (compatibility with all blood groups) its ability to bind 40 times more oxygen than human hemoglobin its particularly small size: 250 times smaller than the human red blood cell

2

Funding Rounds

$150.0m

Money raised

A biopharmaceutical company developing scientific, clinical and commercial oxygen-therapeutic agents

Sign up to access our full database

Enter your email and get access to 71,000 + technology companies you can partner with.

Join 29000+ founders, operators, and investors.